Please fill out the form below and we will gladly respond as soon as possible.
A new educational review in the American Society of Clinical Oncology Educational Book, authored by Sophie Jessop, MBBS, and colleagues, examines three persistent gaps in care for adolescents and young adults (AYAs) with sarcoma: clinical trial access, genetic testing for inherited cancer risk, and timely palliative care. The piece is grounded by the firsthand perspective […]
A new profile by Mariella Bodemeier Loayza Careaga, PhD, published in The Scientist, revisits biochemist Cigall Kadoch’s research nearly a decade after the publication first covered her work, tracing how her lab has continued to map the molecular hijacking that drives synovial sarcoma. The BAF Complex and the SS18-SSX Fusion Kadoch’s research centers on BAF […]
The Synovial Sarcoma Foundation is excited to announce that we have funded a new Data Staff Scientist position at Children’s Hospital of Philadelphia (CHOP), Philadelphia Campus, a major step forward in our mission to accelerate research and improve outcomes for patients with synovial sarcoma. What This Role Will Do The person selected for this role […]
Synovial sarcoma is a rare and aggressive soft tissue cancer, but new research is helping us better understand how it behaves—and how it may be treated in the future. A recent study using advanced single-cell RNA sequencing has identified four distinct subtypes of synovial sarcoma, each with unique biological features and potential treatment pathways. Why […]
A recent case report highlights a rare GLI1-altered mesenchymal tumor presenting in the pleura (lining of the lung), a location where tumors can closely resemble synovial sarcoma. This case underscores a critical challenge in rare cancers — different tumors can appear similar under imaging and even under the microscope, making accurate diagnosis essential for appropriate […]
Recent industry analyses show that the synovial sarcoma clinical trial pipeline is expanding, with more than 15 companies developing over 20 investigational therapies aimed at improving treatment options for this rare cancer. Although synovial sarcoma remains difficult to treat, the growing number of clinical trials reflects increasing research investment and scientific focus on this disease. […]
Synovial sarcoma is a rare soft tissue sarcoma most commonly treated with surgery, chemotherapy, radiation therapy, and targeted drugs such as pazopanib. However, treatment options can be limited for advanced or metastatic disease. A recently published case report describes a patient with synovial sarcoma who achieved a complete response after receiving targeted therapy based on […]
Synovial sarcoma is a rare and often aggressive cancer that can become difficult to treat once it spreads. Traditional chemotherapy options are limited, and outcomes for metastatic disease remain poor. New research is exploring whether advanced T-cell therapies may offer another option. A recent clinical trial evaluated afamitresgene autoleucel (afami-cel), an engineered T-cell therapy designed […]
A recent market analysis estimates that the global synovial sarcoma treatment market was valued at approximately $832 million in 2023 and is projected to reach $1.6 billion by 2031. While market reports focus on financial projections, they often reflect broader trends in research, drug development, and clinical trial activity. For the synovial sarcoma community, this […]
Content Warning:This article references a published medical case study that includes graphic surgical images involving the head and neck region. While the information may be valuable and informative, some readers may find the images difficult to view. Please proceed with care. Synovial sarcoma most often develops in the extremities, but in rare cases, it can […]
